为缺血性心肌病进行重血管化
Matthew E Li Kam Wa1, Saba Z Assar2, Ajay J Kirtane2,3
1Coronary Research Group, British Heart Foundation Centre of Research Excellence, King's College London London, UK.
Interventional cardiology (London, England)
|September 1, 2023
概括
穿皮冠状动脉干预可以为冠状动脉疾病心力衰竭患者提供类似于绕道手术的好处,但没有手术风险. REVIVED-BCIS2试验为这种方法提供了新的见解.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 心脏衰竭研究研究
背景情况:
- 冠状动脉疾病 (CAD) 是心力衰竭的首要原因之一,其中包括心力衰竭的减少射出分数 (HFrEF).
- 冠状动脉旁路移植 (CABG) 改善了生活质量和长期结果,但在严重受损左心室 (LV) 功能的患者中,具有显著的短期风险.
- 对于缺血性心肌病患者来说,最佳的再血管化策略仍然是一个临床挑战.
研究的目的:
- 评估皮肤穿冠状动脉干预 (PCI) 的疗效和安全性,与患有缺血性LV功能障碍的患者的最佳医疗疗 (OMT) 相比.
- 评估PCI是否可以提供与CABG相似的好处,而没有相关的外科手术风险.
- 为了在稳定的CAD和HFrEF患者中提供关于重血管化的临床决策信息.
主要方法:
- REVIVED-BCIS2试验 (NCT01920048) 是一个随机对照试验.
- 它比较了PCI加OMT与单独OMT在患有缺血性心肌病和可活LV心肌病的患者的结果.
- 关键的终点包括死亡率,心力衰竭住院和生活质量指标.
主要成果:
- 在本综述中,试验结果被详细检查.
- 初步发现表明PCI可能在选定的患者中起作用,但进一步的分析正在进行中.
- 该评论讨论了这项试验对临床实践和未来研究方向的影响.
结论:
- REVIVED-BCIS2试验提供了关于PCI在缺血性心肌病中的作用的关键数据.
- 本综述提出了一种潜在的途径,用于患者选择和重血管化决策.
- 探讨了关于PCI的长期益处和最佳患者个人资料的未回答的问题.
相关概念视频
01:29Cardiomyopathy V: Interprofessional Care
14
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
12
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
12
01:30Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
01:14Myocarditis III: Medical Management
7
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
7
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
01:28Acute Coronary Syndrome IV: Interprofessional Care
12
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
12